(Q33504241)
Statements
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks (English)
Rampling R
Graham MA
Wilson P
Robin H Jr
Eckardt N
Lawson N
McDonald A
von Roemeling R
Workman P
1 January 1997